Table 2. Baseline characteristics of patients and medical therapy upon hospital admission.
| N = 593 | N (%)/median (5th; 95th percentile) |
|---|---|
| Sex (female) | 149 (25.1%) |
| Age (years) | 63 (45; 79) |
| Height (cm) | 174 (159; 185) |
| Weight (kg) | 82 (63; 109) |
| Body mass index (kg/m2) | 28.0 (22.0; 35.0) |
| Systolic blood pressure (mmHg) | 140 (90; 185) |
| Diastolic blood pressure (mmHg) | 80 (55; 105) |
| Heart rate (min–1) | 73 (52; 107) |
| Smoker | 254 (42.8%) |
| Previous unstable angina pectoris | 205 (34.6%) |
| Hypertension | 335 (56.5%) |
| Diabetes mellitus | 160 (27.0%) |
| Hyperlipoproteinaemia | 493 (83.1%) |
| History of myocardial infarction | 72 (12.1%) |
| History of PCI/CABG | 39 (6.6%) |
| History of stroke or TIA | 30 (5.1%) |
| Chronic obstructive pulmonary disease | 19 (3.2%) |
| Atrial fibrillation | 13 (2.2%) |
| Chronic angina pectoris | 84 (14.1%) |
| Anti-aggregation (upon admission) | 119 (20.1%) |
| ACEI and/or ARB (upon admission) | 184 (31.0%) |
| Beta-blockers (upon admission) | 158 (26.6%) |
| Statins (upon admission) | 98 (16.5%) |
| *Adverse event during hospitalisation | 23 (3.9%) |
| AHF mild (Killip II) | 127 (21.4%) |
| Pulmonary oedema (Killip III) | 14 (2.4%) |
| Cardiogenic shock (Killip IV) | 22 (3.7%) |
| Time to treatment (min) | 238 (124; 660) |
*Recurrent MI, stroke, major bleed, CHF/shock, arrhythmia, renal failure;
MI—myocardial infarction, ACEI—angiotensin-converting enzyme inhibitor, ARB—angiotensin II receptor blockers, PCI—percutaneous coronary intervention, CABG—coronary artery bypass grafting, TIA—transient ischaemic attack, AHF—acute heart failure.